Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020;25(9):e1406–13.

Article  PubMed  PubMed Central  Google Scholar 

van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–27.

Article  PubMed  Google Scholar 

Tacchetti P, Pantani L, Patriarca F, Petrucci MT, Zamagni E, Dozza L, et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020;7(12):e861–73.

Article  PubMed  Google Scholar 

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132–41.

Article  CAS  PubMed  Google Scholar 

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the harmony project. J Clin Oncol. 2022;40(29):3406–18.

Article  CAS  PubMed  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.

Article  PubMed  Google Scholar 

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.

Article  PubMed  Google Scholar 

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17.

Article  PubMed  Google Scholar 

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302–12.

Article  PubMed  Google Scholar 

Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8(1):268.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.

Article  CAS  PubMed  Google Scholar 

Li J, Zhang X, Qin C, Sun X, Xu X, Cao G, et al. A prognostication system based on clinical parameters and [(18)F]-FDG PET/CT in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2023;50(6):1665–70.

Article  CAS  PubMed  Google Scholar 

Kraeber-Bodere F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, et al. Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study. Haematologica. 2023;108(2):621–6.

Article  PubMed  Google Scholar 

Sachpekidis C, Merz M, Raab MS, Bertsch U, Weru V, Kopp-Schneider A, et al. The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res. 2021;11(1):100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43(3):414–21.

Article  CAS  PubMed  Google Scholar 

Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45(5):712–9.

Article  PubMed  Google Scholar 

Nanni C. PET-FDG: impetus. Cancers Basel. 2020;12(4):1030.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, et al. The role of (18)F-FDG PET/CT in multiple myeloma staging according to IMPeTUs: comparison of the durie-salmon plus and other staging systems. Contrast Media Mol Imaging. 2018;2018:4198673.

Article  PubMed  PubMed Central  Google Scholar 

Sachpekidis C, Enqvist O, Ulen J, Kopp-Schneider A, Pan L, Mai EK, et al. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [(18)F]FDG PET/CT predicts survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2024. https://doi.org/10.1007/s00259-024-06668-z.

Article  PubMed  Google Scholar 

Alberge JB, Kraeber-Bodere F, Jamet B, Touzeau C, Caillon H, Wuilleme S, et al. Molecular signature of (18)F-FDG PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study. J Nucl Med. 2022;63(7):1008–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53(12):1829–35.

Article  CAS  PubMed  Google Scholar 

McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. Assessment of total lesion glycolysis by (18)F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;23(8):1981–7.

Article  CAS  PubMed  Google Scholar 

Terao T, Machida Y, Tsushima T, Miura D, Narita K, Kitadate A, et al. Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. Br J Haematol. 2020;191(2):223–30.

Article  CAS  PubMed  Google Scholar 

Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L. Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. Ann Hematol. 2020;99(1):127–35.

Article  CAS  PubMed  Google Scholar 

Wan B, Zhang S, Wang P, Deng P, Dai W. Prognostic value of semi-quantitative parameters of (18)F-FDG PET/CT in newly diagnosed multiple myeloma patients. Ann Nucl Med. 2023;37(3):155–65.

Article  CAS  PubMed  Google Scholar 

Lee H, Hyun SH, Cho YS, Moon SH, Choi JY, Kim K, et al. Cluster analysis of autoencoder-extracted FDG PET/CT features identifies multiple myeloma patients with poor prognosis. Sci Rep. 2023;13(1):7881.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Terao T, Machida Y, Narita K, Kuzume A, Tabata R, Tsushima T, et al. Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma. Eur Radiol. 2021;31(8):6136–44.

Article  CAS  PubMed  Google Scholar 

Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, et al. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2021;48(4):1005–15.

Article